Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2002-05-31
2008-09-23
McGarry, Sean (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S325000, C435S375000, C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07427470
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6165786 (2000-12-01), Bennett et al.
patent: 6180353 (2001-01-01), Dean et al.
patent: 6444466 (2002-09-01), Ward et al.
Branch, A. A Good Antisense is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells, 2000, vol. 18:307-319.
Dias et al. Potential roles of antisense oligonucletides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics, 2002 vol. 54:263-269.
Matsuda et al. Moleuclar cloning and characterization of a novel human gene (HERNA) which encodes a putative RNA-helicase. Biochimica et Biophysica Acta, 2000 vol. 1490:163-169.
Montgomery et al. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends in Genetics, 1998 vol. 14:255-259.
Dykxhoorn et al. Killing the messenger: Short RNas that silence gene expression. Nature Reviews Molecular Cell Biology, 2003, vol. 4:457-467.
Agrawal et al. Antisense therapeutics: is it as simple as complementary base recognition? Molecular Medicine Today, 2000, vol. 6:72-81.
Tabara et al. The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExH-Box Helicase to direct RNAi in c. elegans. Cell, 2002 vol. 109 :861-871.
Merriam Webster's Collegiate Dictionary, Tenth Edition, Springfield, Massachusetts, 1996, p. 819, at definition of “organism”.
Gura, T. Cancer Models: Systems for identifying New Drugs are Often Faulty. Science, 1997 vol. 278:1041-.
Braasch et al. Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression. Biochemistry, 2002 vol. 41:4503-4510.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci., 1996 vol. 93:3161-3163.
Shoji et al. Current Status of Delivery Systems to Improve Target Efficacy of Oligonucleotides. Current Pharmaceutical Design, 2004 vol. 10:785-796.
Crooke, S. 1998, Basic Principles of Anitsense Therapeutics, Springer-Verlag, NY, pp. 1-50.
Hammond et al. Post-Transcriptional Gene Silencing by Double-Stranded RNA. Nature Reviews, 2001 vol. 2:110-119.
Milligan et al. Current Concepts in Antisense Drug Design. Journal of Medicinal Chemistry, 1993 vol. 36:1923-1937.
Agrawal et al. Antisense therapeutics: is it as simple as complemenatary base recognition? Molecular Medicine Today, 2000 vol. 6:72-81.
Cogoni et al.,Posttranscriptional gene silencing in Neurospora by a RecQ DNA helicase, Science, 1999, 286:2342-2344.
de la Cruz et al.,Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families, Trends Biochem. Sci., 1999, 24:192-198.
Matsuda et al.,Molecular cloning and characterization of a novel human gene(HERNA)which encodes a putative RNA-helicase, Biochim. Biophys. Acta,2000, 1490:163-169.
Nagase et al.,Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro, DNA Res., 1999, 6:63-70.
Provost et al.,Interaction of 5-lipoxygenase with cellular proteins, Proc. Natl. Acad. Sci. U. S. A., 1999, 96:1881-1885.
Bennett, C. F. et al., “Pharmacology of Antisense Therapeutics Agents,”Methods in Molecular Medicine: Antisense Therapeutics(1996) Agrawal, S. (ed.), Humana Press, Inc., Totowa, pp. 13-46.
Flanagan, W. M. et al., “Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide,”Nature Biotech. (1999) 17:48-52.
Green, D. W. et al., “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,”J. Am. coll. Surg. (2000) 191(1):93-105.
Ma, D. D. F. et al., “Synthetic oligonucleotides as therapeutics: the coming of age,”Biotech. Ann. Rev. (2000) 5:155-196.
Taylor, M. F. et al., “Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination,”DDT(1999) 4(12):562-567.
Ward Donna T.
Watt Andrew T.
Gibbs Terra Cotta
Isis Pharmaceuticals , Inc.
Knobbe Martens Olson and Bear LLP
McGarry Sean
LandOfFree
Antisense modulation of helicase-moi expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of helicase-moi expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of helicase-moi expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988866